Search

Each record is a registered study, a systematic-review registration or a publication. A registered or ongoing study is not a finding, and animal or cell research does not show an effect in people. The same study can appear under more than one subject, so the number of records is not a count of independent studies. You can also search an exact DOI, PubMed ID, NCT or CRD number. How to read these records.

40 study records (showing up to 30 per record type)

• Registered trial NCT03161977 Completed (results not assessed here)
  The Effect of Mannitol on the Serum Potassium During Craniotomy
  Condition or outcome area: Mannitol Adverse Reaction|Hyperkalemia
  2017-01-01 · Subject: MTL; Mannitol; d-mannitol; Osmitrol; Mannitol (VAN); 123897-58-5; M9546_SIAL; NCI-C50362; Mannidex; SDM No. 35 · open the ingredient record · ClinicalTrials.gov
• Systematic review registration CRD42020223468 Registered protocol, no results here: Review Ongoing
  Patiromer and Sodium Zirconium Cyclosilicate in hyperkalemia: A systematic review and meta-analysis
  Condition or outcome area: Patiromer calcium and SZC are two new polymer-based, non-systemic agents formulated to increase potassium reduction via the gastrointestinal tract
  2020-12-30 · Subject: Sodium; 7440-23-5; Na; Natrium; Sodio; sodium atom; 116001-96-8; 11Na; DTXSID1049774; CHEBI:26708 · open the ingredient record
• Systematic review registration CRD42020197837 Registered protocol, no results here: Review Ongoing
  Sodium Bicarbonate Administration during Pediatric In-hospital Cardiac Arrest Patients: A Systematic Review and Meta-analysis
  Condition or outcome area: Recent advanced cardiac life support guideline suggested against routine use of sodium bicarbonate for adult cardiac arrest patients except special situations such as metabolic acidosis, hyperkalemia, or tricyclic antidepressant overdose. However, there are limited recommendations for using sodium bicarbonate in pediatric cardiac arrest patients. Despite the adverse effects and limited benefit, administering SB during resuscitation is still common. To our knowledge, no systematic review and meta
  2020-08-08 · Subject: Sodium; 7440-23-5; Na; Natrium; Sodio; sodium atom; 116001-96-8; 11Na; DTXSID1049774; CHEBI:26708 · open the ingredient record
• Systematic review registration CRD42020175277 Registered protocol, no results here: Review Completed published
  Effectiveness of sodium bicarbonate administration on mortality in cardiac arrest patients: a systematic review and meta-analysis
  Condition or outcome area: Due to the possibility of severe metabolic acidosis during resuscitation is concerned, buffer therapy with sodium bicarbonate makes pathophysiologic sense. But the current ACLS guideline suggested against routine use of sodium bicarbonate for cardiac arrest patients except special situations such as metabolic acidosis, hyperkalemia, or tricyclic antidepressant overdose. Despite the adverse effects and limited benefit, administering SB during resuscitation is still common. The inconsistency betwe
  2020-04-28 · Subject: Sodium; 7440-23-5; Na; Natrium; Sodio; sodium atom; 116001-96-8; 11Na; DTXSID1049774; CHEBI:26708 · open the ingredient record
• Systematic review registration CRD42020185614 Registered protocol, no results here: Review Completed not published
  The interest of potassium binding-polymers on the use of renin-angiotensin-aldosterone system inhibitors: pairwise and network meta-analyses of clinical trials and real-world data studies
  Condition or outcome area: The risk of hyperkalemia (serum potassium level (sK+) >5.1 mEq/L) often precludes use of RAASi, well-known cardiovascular drugs, that have indication in the treatment of heart failure (HF), in addition to their indications in hypertension, after myocardial infarction, to kidney protection, etc. However, certain susceptible populations, such as HF patients affected by CKD (diabetics or not), patients with resistant hypertension (i.e., uncontrolled blood pressure when taking three or more class
  2020-07-05 · Subject: Potassium; 7440-09-7; K; Kalium; Potassium, metal; potasio; potassium atom; Potassium metal; DTXSID9049748 · open the ingredient record
• Systematic review registration CRD42020142460 Registered protocol, no results here: Review Ongoing
  What is the evidence for critical risk alert thresholds for potassium results that require immediate medical intervention due to the high risk of imminent death or major patient harm?
  Condition or outcome area: Hypokalemia and Hyperkalemia. Evidence for established critical results thresholds, effective communication and reporting and its impact on patients outcome.
  2020-04-28 · Subject: Potassium; 7440-09-7; K; Kalium; Potassium, metal; potasio; potassium atom; Potassium metal; DTXSID9049748 · open the ingredient record
• Systematic review registration CRD42014014450 Registered protocol, no results here: status not recorded
  The effectiveness of intravenous Lidocaine used to treat pain related to peripheral potassium chloride infusion in adult hospitalized patients: a systematic review protocol
  Condition or outcome area: Hypokalemia disrupts normal homeostasis and occurs in among 20% of hospitalized patients, with the most common cause being the depletion of potassium ions (K+) from gastrointestinal or urinary losses. Intravenous potassium chloride infusion is often used to treat hypokalemia, and is proven to be a relatively safe treatment of hypokalemia in about 20% of the hospitalized patients. However this infusion can cause severe acute pain via a peripherally inserted catheter at the infusion site. The etio
  Subject: Potassium chloride; Potassium Chloride; 7447-40-7; Enseal; Klotrix; Sylvite; Klor-Con; Neobakasal; Muriate of potash; Slow-K · open the ingredient record
• Systematic review registration CRD42014014450 Registered protocol, no results here: status not recorded
  The effectiveness of intravenous Lidocaine used to treat pain related to peripheral potassium chloride infusion in adult hospitalized patients: a systematic review protocol
  Condition or outcome area: Hypokalemia disrupts normal homeostasis and occurs in among 20% of hospitalized patients, with the most common cause being the depletion of potassium ions (K+) from gastrointestinal or urinary losses. Intravenous potassium chloride infusion is often used to treat hypokalemia, and is proven to be a relatively safe treatment of hypokalemia in about 20% of the hospitalized patients. However this infusion can cause severe acute pain via a peripherally inserted catheter at the infusion site. The etio
  Subject: Potassium; 7440-09-7; K; Kalium; Potassium, metal; potasio; potassium atom; Potassium metal; DTXSID9049748 · open the ingredient record
• Systematic review registration CRD42022316641 Registered protocol, no results here: Review Completed published
  Calcium during cardiopulmonary resuscitation: A systematic review and Meta-analysis
  Condition or outcome area: Cardiopulmonary arrest is a devastating condition. Mortality can be high as 84% following an out-of-hospital cardiac arrest. Unfortunately, pharmacological interventions for this condition are limited. Calcium has been used for decades in the setting of cardiopulmonary arrest due to the possibility of improvement on cardiac muscle contraction and vasoconstriction properties. Calcium is also used as treatment for hyperkalemia and hypocalcemia, both causes for cardiac arrest. Until 2021, the liter
  2022-04-13 · Subject: Calcium; 7440-70-2; Ca; Elemental calcium; Calcium, elemental; HSDB 273; UNII-SY7Q814VUP; SY7Q814VUP; EINECS 231-179-5; Kalzium · open the ingredient record
• Systematic review registration CRD42023304661 Registered protocol, no results here: Review Ongoing
  Potassium-Binding Agents for Hyperkalemia: A Network Meta-Analysis
  Condition or outcome area: Hyperkalemia in adult patients.
  2023-02-03 · Subject: Potassium; 7440-09-7; K; Kalium; Potassium, metal; potasio; potassium atom; Potassium metal; DTXSID9049748 · open the ingredient record
• Systematic review registration CRD42020191430 Registered protocol, no results here: Review Completed not published
  Binding potassium for dialysis patients: Systematic review and meta-analysis on clinical trials and real-world data studies
  Condition or outcome area: Hyperkalemia 􏰆􏰆􏰇􏰈􏰉(serum potassium level (sK+) >5.1 mmol/L) limits the use of RAASi and other HKID, such as β-blockers, to treat cardiovascular disease and its consequences in dialysis patients. Indeed, in most cases, only dialysis is the way to correct this ion alteration in such patients, and, to date, no pharmacological options may be envisaged as optimaly efficacious. This systematic review is intended to retrieve all evidence on binding potassium to avoid this worrying situation.
  2020-07-10 · Subject: Potassium; 7440-09-7; K; Kalium; Potassium, metal; potasio; potassium atom; Potassium metal; DTXSID9049748 · open the ingredient record
• Systematic review registration CRD42020185558 Registered protocol, no results here: Review Completed not published
  Potassium binding for non-acute hyperkalemia: Pairwise and network meta-analyses of clinical trials and real-world data studies
  Condition or outcome area: Hyperkalemia (serum potassium level (sK+) >5.1 mmol/L) is associated with increased mortality among patients with heart failure (HF), who are frequently affected by chronic kidney disease (CKD) and diabetes mellitus (DM), and need treatment with RAASi including almost obligatorily a mineralocorticoid receptor antagonist (MRA), and take other hyperkalemia-inducing drugs (HKID), such as β-blockers. Nevertheless, hyperkalemia is also an important concern among patients with resistant hypertensio
  2020-07-05 · Subject: Potassium; 7440-09-7; K; Kalium; Potassium, metal; potasio; potassium atom; Potassium metal; DTXSID9049748 · open the ingredient record
• Publication PMID 34064189 Research model: Animal Experiment
  Protective Effect of Curcumin against Sodium Salicylate-Induced Oxidative Kidney Damage, Nuclear Factor-Kappa Dysregulation, and Apoptotic Consequences in Rats
  Condition or outcome area: hypomagnesemia; neutrophilia; hyperphosphatemia; hyperkalemia; hypocalcemia; thrombocytopenia; hyponatremia; leukocytosis; hypochloremia
  Antioxidants (Basel) · 2021 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record · DOI 10.3390/antiox10060826
• Publication PMID 36462602 Research model: Animal Experiment
  Baicalein exerts anxiolytic and antinociceptive effects in a mouse model of posttraumatic stress disorder: Involvement of the serotonergic system and spinal delta-opioid receptors
  Condition or outcome area: chronic pain; stress dysfunction; mental disease; depression; neuropathic pain; Post-traumatic stress disorder; anxiety
  Prog Neuropsychopharmacol Biol Psychiatry · 2022 · Subject: Baicalein; 491-67-8; 5,6,7-Trihydroxyflavone; Noroxylin; 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one; Biacalein; BaiKalein; 5,6,7-trihydroxy-2-phenylchromen-4-one; MFCD00017459; NSC 661431 · open the ingredient record · DOI 10.1016/j.pnpbp.2022.110689
• Publication PMID 36388170 Research model: Animal Experiment
  Baicalein Alleviates Testicular Ischemia-Reperfusion Injury in a Rat Model of Testicular Torsion-Detorsion
  Condition or outcome area: Testicular torsion/detorsion-induced ischemia/reperfusion injury; testicular ischemia-reperfusion injury; tumor
  Oxid Med Cell Longev · 2022 · Subject: Baicalein; 491-67-8; 5,6,7-Trihydroxyflavone; Noroxylin; 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one; Biacalein; BaiKalein; 5,6,7-trihydroxy-2-phenylchromen-4-one; MFCD00017459; NSC 661431 · open the ingredient record · DOI 10.1155/2022/1603469
• Publication PMID 36070933 Research model: Cell Experiment
  miR-3,178 contributes to the therapeutic action of baicalein against hepatocellular carcinoma cells via modulating HDAC10
  Condition or outcome area: cancers; Hepatocellular carcinoma; tumor; hepatic malignancies
  Phytother Res · 2022 · Subject: Baicalein; 491-67-8; 5,6,7-Trihydroxyflavone; Noroxylin; 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one; Biacalein; BaiKalein; 5,6,7-trihydroxy-2-phenylchromen-4-one; MFCD00017459; NSC 661431 · open the ingredient record · DOI 10.1002/ptr.7613
• Publication PMID 35847050 Research model: Animal Experiment
  Baicalein Prevents Fructose-Induced Hepatic Steatosis in Rats: In the Regulation of Fatty Acid De Novo Synthesis, Fatty Acid Elongation and Fatty Acid Oxidation
  Condition or outcome area: steatosis; liver diseases; non-alcoholic steatohepatitis; hepatocellular carcinoma; Non-alcoholic fatty liver disease; hepatic fibrosis; liver disease
  Front Pharmacol · 2022 · Subject: Baicalein; 491-67-8; 5,6,7-Trihydroxyflavone; Noroxylin; 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one; Biacalein; BaiKalein; 5,6,7-trihydroxy-2-phenylchromen-4-one; MFCD00017459; NSC 661431 · open the ingredient record · DOI 10.3389/fphar.2022.917329
• Publication PMID 35806375 Research model: Animal Experiment
  Mechanistic Effects of Baicalein on Aqueous Humor Drainage and Intraocular Pressure
  Condition or outcome area: hTM; glaucoma
  Int J Mol Sci · 2022 · Subject: Baicalein; 491-67-8; 5,6,7-Trihydroxyflavone; Noroxylin; 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one; Biacalein; BaiKalein; 5,6,7-trihydroxy-2-phenylchromen-4-one; MFCD00017459; NSC 661431 · open the ingredient record · DOI 10.3390/ijms23137372
• Publication PMID 35749304 Research model: Cell Experiment
  Baicalein inhibits macrophage lipid accumulation and inflammatory response by activating the PPARγ/LXRα pathway
  Condition or outcome area: atherosclerosis
  Clin Exp Immunol · 2022 · Subject: Baicalein; 491-67-8; 5,6,7-Trihydroxyflavone; Noroxylin; 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one; Biacalein; BaiKalein; 5,6,7-trihydroxy-2-phenylchromen-4-one; MFCD00017459; NSC 661431 · open the ingredient record · DOI 10.1093/cei/uxac062
• Publication PMID 35624812 Research model: Animal Experiment
  Baicalein Exerts Therapeutic Effects against Endotoxin-Induced Depression-like Behavior in Mice by Decreasing Inflammatory Cytokines and Increasing Brain-Derived Neurotrophic Factor Levels
  Condition or outcome area: inflammation
  Antioxidants (Basel) · 2022 · Subject: Baicalein; 491-67-8; 5,6,7-Trihydroxyflavone; Noroxylin; 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one; Biacalein; BaiKalein; 5,6,7-trihydroxy-2-phenylchromen-4-one; MFCD00017459; NSC 661431 · open the ingredient record · DOI 10.3390/antiox11050947
• Publication PMID 35306368 Research model: Animal & Cell Experiment
  The molecular mechanism of baicalein repressing progression of gastric cancer mediating miR-7/FAK/AKT signaling pathway
  Condition or outcome area: gastric cancer; cancers; tumor; Gastric cancer
  Phytomedicine · 2022 · Subject: Baicalein; 491-67-8; 5,6,7-Trihydroxyflavone; Noroxylin; 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one; Biacalein; BaiKalein; 5,6,7-trihydroxy-2-phenylchromen-4-one; MFCD00017459; NSC 661431 · open the ingredient record · DOI 10.1016/j.phymed.2022.154046
• Publication PMID 34966284 Research model: Animal Experiment
  Baicalein Ameliorates Aβ-Induced Memory Deficits and Neuronal Atrophy via Inhibition of PDE2 and PDE4
  Condition or outcome area: Abeta-induced neuronal atrophy; dementias; anti-Alzheimer's disease; cognitive impairment; memory impairment; cognitive disorder
  Front Pharmacol · 2021 · Subject: Baicalein; 491-67-8; 5,6,7-Trihydroxyflavone; Noroxylin; 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one; Biacalein; BaiKalein; 5,6,7-trihydroxy-2-phenylchromen-4-one; MFCD00017459; NSC 661431 · open the ingredient record · DOI 10.3389/fphar.2021.794458
• Publication PMID 34671110 Research model: Animal Experiment
  Baicalein ameliorates ulcerative colitis by improving intestinal epithelial barrier via AhR/IL-22 pathway in ILC3s
  Condition or outcome area: gut barrier dysfunction; colitis; chronic inflammatory disease of the gastrointestinal tract; Ulcerative colitis
  Acta Pharmacol Sin · 2021 · Subject: Baicalein; 491-67-8; 5,6,7-Trihydroxyflavone; Noroxylin; 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one; Biacalein; BaiKalein; 5,6,7-trihydroxy-2-phenylchromen-4-one; MFCD00017459; NSC 661431 · open the ingredient record · DOI 10.1038/s41401-021-00781-7
• Publication PMID 34512868 Research model: Animal Experiment
  Intra-articular Injection of Baicalein Inhibits Cartilage Catabolism and NLRP3 Inflammasome Signaling in a Posttraumatic OA Model
  Condition or outcome area: OA-related inflammation; osteoarthritis; cartilage degeneration; Osteoarthritis
  Oxid Med Cell Longev · 2021 · Subject: Baicalein; 491-67-8; 5,6,7-Trihydroxyflavone; Noroxylin; 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one; Biacalein; BaiKalein; 5,6,7-trihydroxy-2-phenylchromen-4-one; MFCD00017459; NSC 661431 · open the ingredient record · DOI 10.1155/2021/6116890
• Publication PMID 34512367 Research model: Clinical Experiment
  Baicalein Potentiated M1 Macrophage Polarization in Cancer Through Targeting PI3Kγ/ NF-κB Signaling
  Condition or outcome area: melanoma; tumor; breast cancer
  Front Pharmacol · 2021 · Subject: Baicalein; 491-67-8; 5,6,7-Trihydroxyflavone; Noroxylin; 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one; Biacalein; BaiKalein; 5,6,7-trihydroxy-2-phenylchromen-4-one; MFCD00017459; NSC 661431 · open the ingredient record · DOI 10.3389/fphar.2021.743837
• Publication PMID 34207230 Research model: Animal Experiment
  Inhibition of Oxidative Stress and ALOX12 and NF-κB Pathways Contribute to the Protective Effect of Baicalein on Carbon Tetrachloride-Induced Acute Liver Injury
  Condition or outcome area: ferroptosis; acute liver injury
  Antioxidants (Basel) · 2021 · Subject: Baicalein; 491-67-8; 5,6,7-Trihydroxyflavone; Noroxylin; 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one; Biacalein; BaiKalein; 5,6,7-trihydroxy-2-phenylchromen-4-one; MFCD00017459; NSC 661431 · open the ingredient record · DOI 10.3390/antiox10060976
• Publication PMID 34008261 Research model: Cell Experiment
  Targeting inflammation-associated AMPK//Mfn-2/MAPKs signaling pathways by baicalein exerts anti-atherosclerotic action
  Condition or outcome area: atherosclerosis
  Phytother Res · 2021 · Subject: Baicalein; 491-67-8; 5,6,7-Trihydroxyflavone; Noroxylin; 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one; Biacalein; BaiKalein; 5,6,7-trihydroxy-2-phenylchromen-4-one; MFCD00017459; NSC 661431 · open the ingredient record · DOI 10.1002/ptr.7149
• Publication PMID 33996574 Research model: Cell Experiment
  Baicalein Induces Apoptosis of Pancreatic Cancer Cells by Regulating the Expression of miR-139-3p and miR-196b-5p
  Condition or outcome area: malignant tumor; pancreatic cancer; Pancreatic cancer; cancer
  Front Oncol · 2021 · Subject: Baicalein; 491-67-8; 5,6,7-Trihydroxyflavone; Noroxylin; 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one; Biacalein; BaiKalein; 5,6,7-trihydroxy-2-phenylchromen-4-one; MFCD00017459; NSC 661431 · open the ingredient record · DOI 10.3389/fonc.2021.653061
• Publication PMID 33579328 Research model: Others
  Baicalein inhibits heparin-induced Tau aggregation by initializing non-toxic Tau oligomer formation
  Condition or outcome area: neurodegeneration; Alzheimer's disease; cognitive inabilities; Alzheimer's; neurodegenerative diseases; neuroblastoma; Parkinson's; neuronal dysfunction; Prion diseases; memory loss; brain atrophy
  Cell Commun Signal · 2021 · Subject: Baicalein; 491-67-8; 5,6,7-Trihydroxyflavone; Noroxylin; 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one; Biacalein; BaiKalein; 5,6,7-trihydroxy-2-phenylchromen-4-one; MFCD00017459; NSC 661431 · open the ingredient record · DOI 10.1186/s12964-021-00704-3
• Publication PMID 33354504 Research model: Animal Experiment
  Inhibitory effects of baicalein against herpes simplex virus type 1
  Condition or outcome area: encephalitis; HSV-1 infection; cold sores; corneal blindness; Herpes simplex virus type 1 (HSV-1
  Acta Pharm Sin B · 2020 · Subject: Baicalein; 491-67-8; 5,6,7-Trihydroxyflavone; Noroxylin; 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one; Biacalein; BaiKalein; 5,6,7-trihydroxy-2-phenylchromen-4-one; MFCD00017459; NSC 661431 · open the ingredient record · DOI 10.1016/j.apsb.2020.06.008
• Publication PMID 33121927 Research model: Animal & Cell Experiment
  The comprehensive study on the therapeutic effects of baicalein for the treatment of COVID-19 in vivo and in vitro
  Condition or outcome area: SARS-CoV-2; acute lung injury
  Biochem Pharmacol · 2021 · Subject: Baicalein; 491-67-8; 5,6,7-Trihydroxyflavone; Noroxylin; 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one; Biacalein; BaiKalein; 5,6,7-trihydroxy-2-phenylchromen-4-one; MFCD00017459; NSC 661431 · open the ingredient record · DOI 10.1016/j.bcp.2020.114302
• Publication PMID 32796955 Research model: Animal Experiment
  Baicalein attenuates cardiac hypertrophy in mice via suppressing oxidative stress and activating autophagy in cardiomyocytes
  Condition or outcome area: cardiac hypertrophy; Cardiac hypertrophy
  Acta Pharmacol Sin · 2021 · Subject: Baicalein; 491-67-8; 5,6,7-Trihydroxyflavone; Noroxylin; 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one; Biacalein; BaiKalein; 5,6,7-trihydroxy-2-phenylchromen-4-one; MFCD00017459; NSC 661431 · open the ingredient record · DOI 10.1038/s41401-020-0496-1
• Publication PMID 32761175 Research model: Animal Experiment
  Baicalein Attenuates Neuroinflammation by Inhibiting NLRP3/caspase-1/GSDMD Pathway in MPTP Induced Mice Model of Parkinson's Disease
  Condition or outcome area: motor dysfunction; neurodegenerative diseases; Parkinson's disease; degeneration of nigral dopaminergic
  Int J Neuropsychopharmacol · 2020 · Subject: Baicalein; 491-67-8; 5,6,7-Trihydroxyflavone; Noroxylin; 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one; Biacalein; BaiKalein; 5,6,7-trihydroxy-2-phenylchromen-4-one; MFCD00017459; NSC 661431 · open the ingredient record · DOI 10.1093/ijnp/pyaa060
• Publication PMID 32691974 Research model: Others
  Baicalein inhibits non-small-cell lung cancer invasion and metastasis by reducing ezrin tension in inflammation microenvironment
  Condition or outcome area: cancers; non-small-cell lung cancer
  Cancer Sci · 2020 · Subject: Baicalein; 491-67-8; 5,6,7-Trihydroxyflavone; Noroxylin; 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one; Biacalein; BaiKalein; 5,6,7-trihydroxy-2-phenylchromen-4-one; MFCD00017459; NSC 661431 · open the ingredient record · DOI 10.1111/cas.14577
• Publication PMID 32526964 Research model: Cell Experiment
  Baicalein Inhibits Benzo[a]pyrene-Induced Toxic Response by Downregulating Src Phosphorylation and by Upregulating NRF2-HMOX1 System
  Antioxidants (Basel) · 2020 · Subject: Baicalein; 491-67-8; 5,6,7-Trihydroxyflavone; Noroxylin; 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one; Biacalein; BaiKalein; 5,6,7-trihydroxy-2-phenylchromen-4-one; MFCD00017459; NSC 661431 · open the ingredient record · DOI 10.3390/antiox9060507
• Publication PMID 31909773 Research model: Animal & Cell Experiment
  Baicalein reduces hepatic fat accumulation by activating AMPK in oleic acid-induced HepG2 cells and high-fat diet-induced non-insulin-resistant mice
  Condition or outcome area: liver disease; Nonalcoholic fatty liver disease
  Food Funct · 2020 · Subject: Baicalein; 491-67-8; 5,6,7-Trihydroxyflavone; Noroxylin; 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one; Biacalein; BaiKalein; 5,6,7-trihydroxy-2-phenylchromen-4-one; MFCD00017459; NSC 661431 · open the ingredient record · DOI 10.1039/c9fo02237f
• Publication PMID 31746368 Research model: Cell Experiment
  Baicalein inhibits the growth of oral squamous cell carcinoma cells by downregulating the expression of transcription factor Sp1
  Condition or outcome area: oral cancer; tumor; Oral squamous cell carcinoma; malignancy of the oral cavity
  Int J Oncol · 2020 · Subject: Baicalein; 491-67-8; 5,6,7-Trihydroxyflavone; Noroxylin; 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one; Biacalein; BaiKalein; 5,6,7-trihydroxy-2-phenylchromen-4-one; MFCD00017459; NSC 661431 · open the ingredient record · DOI 10.3892/ijo.2019.4894
• Publication PMID 25948105 Research model: Cell Experiment
  Baicalein increases the expression and reciprocal interplay of RUNX3 and FOXO3a through crosstalk of AMPKα and MEK/ERK1/2 signaling pathways in human non-small cell lung cancer cells
  J Exp Clin Cancer Res · 2015 · Subject: Baicalein; 491-67-8; 5,6,7-Trihydroxyflavone; Noroxylin; 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one; Biacalein; BaiKalein; 5,6,7-trihydroxy-2-phenylchromen-4-one; MFCD00017459; NSC 661431 · open the ingredient record · DOI 10.1186/s13046-015-0160-7
• Publication PMID 28859441 Research model: Animal Experiment
  Baicalein acts as a nephroprotectant that ameliorates colistin-induced nephrotoxicity by activating the antioxidant defence mechanism of the kidneys and down-regulating the inflammatory response
  J Antimicrob Chemother · 2017 · Subject: Baicalein; 491-67-8; 5,6,7-Trihydroxyflavone; Noroxylin; 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one; Biacalein; BaiKalein; 5,6,7-trihydroxy-2-phenylchromen-4-one; MFCD00017459; NSC 661431 · open the ingredient record · DOI 10.1093/jac/dkx185
• Publication PMID 31000696 Research model: Animal Experiment
  Baicalein inhibits fibronectin-induced epithelial-mesenchymal transition by decreasing activation and upregulation of calpain-2
  Condition or outcome area: Breast cancer
  Cell Death Dis · 2019 · Subject: Baicalein; 491-67-8; 5,6,7-Trihydroxyflavone; Noroxylin; 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one; Biacalein; BaiKalein; 5,6,7-trihydroxy-2-phenylchromen-4-one; MFCD00017459; NSC 661431 · open the ingredient record · DOI 10.1038/s41419-019-1572-7